Navigation Links
CV Therapeutics Announces Topline MERLIN TIMI-36 Results

- Full study results will be presented at the American College of Cardiology's Scientific Session -

PALO ALTO, Calif., March 06, 2007 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. announced today that an analysis of unblinded data from the MERLIN TIMI-36 study of ranolazine shows there was no adverse trend in death or arrhythmias in patients on ranolazine. The study did not meet the primary efficacy endpoint.

In accordance with the company's special protocol assessment agreement with the U.S. Food and Drug Administration (FDA), the company believes that the data could support expansion of the existing Ranexa(R) (ranolazine extended-release tablets) indication to include first line angina.

Complete data are scheduled to be presented as a late breaking clinical trial on Tuesday, March 27 at 8:50 a.m. central time during the 2007 of Cardiology Scientific Session in New Orleans.

Study Design

MERLIN TIMI-36 (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes) is a multi-national, double-blind, randomized, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of Ranexa during acute and long-term treatment in approximately 6,500 patients with non-ST elevation ACS treated with standard therapy.

Within 48 hours of the onset of angina due to ACS, eligible hospitalized patients were enrolled in the study and randomized to receive intravenous Ranexa or placebo, followed by long-term outpatient treatment with Ranexa extended-release tablets or placebo. All patients also received standard therapy during both hospital-based and outpatient treatment. The doses of Ranexa extended-release tablets used in MERLIN TIMI-36 have been studied in previous Phase 3 clinical trials.

Currently, Ranexa is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with
'"/>




Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Therapeutics Announces Topline MERLIN TIMI Results
(Date:7/10/2014)... Utah , July 10, 2014  BC Technical, ... and MiE America , Inc., a leading provider ... entered into a long-term agreement naming BC Technical as ... US. MiE and BC Technical announced ... agreement to establish BC Technical as the service and ...
(Date:7/10/2014)... Mass. , July 10, 2014  Decision ... of surveyed infectious disease (ID) specialists are willing ... Company,s Orbactiv (oritavancin) for use as OPAT, approximately ... prescribe these agents to their hospital inpatients. However, ... of OPAT patients are initiated on OPAT following ...
(Date:7/10/2014)... , July 10, 2014 Decision Resources Group ... of the U.S. Food and Drug Administration,s (FDA) approval ... binder Velphoro, which was approved by the FDA in ... kidney disease (CKD) patients on dialysis. Other ... Nephrology (US) Q2 2014 : ...
Breaking Medicine Technology:BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3
... Inc. (Nasdaq: ANTH ), today announced financial results ... Financial Results: Total operating ... $18.7 million, as compared to $6.5 million for the same ... quarter of 2011 were driven by expenses related to site ...
... STAAR Surgical Company (NASDAQ: STAA ), ... ophthalmic products, today reported financial results for the first ... increased 8% to $14.8 million over the first quarter ... (IOL and ICL) sales.  The Company achieved its first ...
Cached Medicine Technology:Anthera Pharmaceuticals Reports 2011 First Quarter Financial Results and Operational Update 2Anthera Pharmaceuticals Reports 2011 First Quarter Financial Results and Operational Update 3Anthera Pharmaceuticals Reports 2011 First Quarter Financial Results and Operational Update 4Anthera Pharmaceuticals Reports 2011 First Quarter Financial Results and Operational Update 5STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 2STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 3STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 4STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 5STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 6STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 7STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 8STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 9STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 10STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 11
(Date:7/13/2014)... The report “Micronutrient Market by Type (Zinc, Manganese, ... Chelated), Application Mode (Soil, Foliar, Fertigation), Crop Type ... 2018” defines and segments the global agriculture micronutrients ... global value and volume for agriculture micronutrients. It ... the global agriculture micronutrients market with an analysis ...
(Date:7/13/2014)... 2014 According to a new ... Market by Component (processor, GPU, DSP, connectivity), Technology ... and Geography - Forecast and Analysis to 2014-2020", ... & Computing Market is expected to reach $61.70 ... 20.75% from 2014 to 2020. , Browse 71 ...
(Date:7/13/2014)... HealthDay Reporter FRIDAY, July 11, 2014 ... people with diabetes is being developed to measure sugar levels ... Scientists at Brown University in Providence, R.I., created the ... light, metal and a special enzyme that changes color when ... to prick their fingers to draw blood to check their ...
(Date:7/13/2014)... New York (PRWEB) July 13, 2014 ... ( http://www.transvaginalmeshlawsuithelp.com/ ) filed against Johnson & ... second bellwether trial, which is expected to get underway ... issued in the U.S. District Court, Southern District of ... will be held on August 7, 2014 at 3:00 ...
(Date:7/13/2014)... MyDressCity.com, one of the most popular suppliers of wedding ... new range of elegant Quinceanera dresses . What’s ... prices. Worldwide clients can enjoy this special offer before ... shop, there are plenty of beautiful dresses for sale, ... MyDressCity.com’s hot items are prom gowns, bridesmaid gowns, wedding ...
Breaking Medicine News(10 mins):Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 4Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2
... repair damage with natural tissue , THURSDAY, Feb. 4 ... cartilage growth in joints has been developed by U.S. ... joint and stimulates bone marrow stem cells to produce ... No current therapy can do this, according to the ...
... typical 30-hour shifts need to be cut to 16 to ... In November 2000, Helen Haskell took her 15-year-old son to ... Four days later, he was dead. The cause: failure to ... to recognize and act upon declines in patients." , He ...
... , GAINESVILLE, Fla. , Feb. 4 ... announce today that they have jointly selected Sg2 , a healthcare ... children,s hospital. The assessment began in January with findings projected to be ... at Sg2 will handle this very important assessment, delivering the ...
... , , TORRANCE, ... the largest privately held insurance brokerage and consulting firm in ... providers of integrated disease management and wellness programs.  Nurtur and ... program providers, adding an important dimension to the company,s extensive ...
... , , NEW YORK , ... Parkinson,s Research today announced more than $2.8 million ... of biomarkers of PD. The development of biomarkers is of ... therapeutic development, allowing scientists and clinicians to more accurately identify ...
... , Feb 4 Smart Balance, Inc. (Nasdaq: SMBL ... February 25, 2010 , at 9:30 a.m. ET to ... 8:30 a.m. ET the same day.  The webcast will be in ... by dialing 1-800-895-0198 from the United States or 1-785-424-1053 from ...
Cached Medicine News:Health News:Nanofiber Gel May Spur Growth of New Knee Cartilage 2Health News:Campaign Calls for Limits on Doctors' Hours 2Health News:Campaign Calls for Limits on Doctors' Hours 3Health News:Sebastian Ferrero Foundation and Shands HealthCare Have Selected Sg2 to Conduct a Needs Assessment for a Gainesville-Based Children's Hospital 2Health News:Sebastian Ferrero Foundation and Shands HealthCare Have Selected Sg2 to Conduct a Needs Assessment for a Gainesville-Based Children's Hospital 3Health News:Keenan Selects Nurtur and Healthyroads for Integrated Disease Management and Personal Wellness Programs 2Health News:Keenan Selects Nurtur and Healthyroads for Integrated Disease Management and Personal Wellness Programs 3Health News:Keenan Selects Nurtur and Healthyroads for Integrated Disease Management and Personal Wellness Programs 4Health News:Michael J. Fox Foundation Awards $2.8 Million to Drive Development of Parkinson's Disease Biomarker Pipeline 2Health News:Michael J. Fox Foundation Awards $2.8 Million to Drive Development of Parkinson's Disease Biomarker Pipeline 3Health News:Michael J. Fox Foundation Awards $2.8 Million to Drive Development of Parkinson's Disease Biomarker Pipeline 4Health News:Smart Balance to Host Webcast/Conference Call on 2009 Fourth-Quarter Results 2
... The MEL 80 is a top quality ... the correction of vision defects even safer, ... of this ultramodern work platform are oriented ... and the rapid recovery of vision. Key ...
Code-Ready defibrillator a defibrillator designed to provide clinicians with comprehensive support for resuscitation....
... be mounted at the patient's bedside, on ... The design retains many of the proven ... the pump drive motor circuits, flow estimator, ... system. Retaining these subsystems maintains compatibility ...
The ARK-730A initiates automatic measurement at the optimum measurement point. The ARK-730A maintains fogging throughout multiple measurements, saving total examination time....
Medicine Products: